Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Poulter, H. Wedel, B. Dahlöf, P. Sever, D. Beevers, M. Caulfield, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Östergren, S. Pocock (2005)
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)The Lancet, 366
J. Foulds, M. Burke, M. Steinberg, Jill Williams, D. Ziedonis (2004)
Advances in pharmacotherapy for tobacco dependence.Expert opinion on emerging drugs, 9 1
(1990)
The health benefits of smoking cessation: a report of the Surgeon General
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
K. Fontaine, I. Barofsky, R. Andersen, S. Bartlett, L. Wiersema, L. Cheskin, S. Franckowiak (1999)
Impact of weight loss on Health-Related Quality of LifeQuality of Life Research, 8
F. Gueyffier, C. Bulpitt, J. Boissel, E. Schron, T. Ekbom, R. Fagard, E. Casiglia, K. Kerlikowske, J. Coope (1999)
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trialsThe Lancet, 353
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
M. Stearne, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, J. Levy, C. Tidy, N. Bell, J. Steemson, B. Barrow, R. Coster, K. Waring, J. Nolan, E. Truscott, N. Walravens, L. Cook, H. Lampard, C. Merle, P. Parker, J. Mcvittie, I. Draisey, L. Murchison, A. Brunt, M. Williams, D. Pearson, X. Petrie, M. Lean, D. Walmsley, M. Lyall, E. Christie, J. Church, E. Thomson, A. Farrow, J. Stowers, M. Stowers, K. McHardy, N. Patterson, A. Wright, N. Levi, A. Shearer, R. Thompson, G. Taylor, S. Rayton, M. Bradbury, A. Glover, A. Smyth-Osbourne, C. Parkes, J. Graham, P. England, S. Gyde, C. Eagle, B. Chakrabarti, J. Smith, J. Sherwell, E. Kohner, A. Dornhurst, M. Doddridge, M. Dumskyj, S. Walji, P. Sharp, M. Sleightholm, G. Vanterpool, C. Rose, G. Frost, M. Roseblade, S. Elliott, S. Forrester, M. Foster, K. Myers, R. Chapman, J. Hayes, R. Henry, M. Featherston, G. Archbold, M. Copeland, R. Harper, I. Richardson, S. Martín, H. Davison, D. Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hegan, H. Tennet, N. Webb, I. Robinson, J. Holmes, P. Bell, D. McCance, J. Rutherford, S. Nesbitt, A. Spathis, S. Hyer, M. Nanson, L. James, J. Tyrell, C. Davis, P. Strugnell, M. Booth, H. Petrie, D. Clark, B. Rice, S. Hulland, J. Barron, J. Yudkin, B. Gould, J. Singer, A. Badenock, M. Eckert, K. Alibhai, E. Marriot, C. Cox, R. Price, M. Fernandez, A. Ryle, S. Clarke, G. Wallace, E. Mehmed, S. Macfarlane, R. Greenwood, J. Wilson, M. Denholm, R. Temple, K. Whitfield, F. Johnson, C. Munroe, S. Gorick, E. Duckworth, M. Flatman, S. Rainbow, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, W. Wheatcroft, P. Musk, J. White, S. McDougal, M. Bond, P. Raniga, R. Newton, R. Jung, C. Roxburgh, B. Kilgallon, L. Dick, N. Waugh, S. Kilby, A. Ellingford, J. Burns, C. Fox, M. Holloway, H. Coghill, N. Hein, A. Fox, W. Cowan, M. Richard, K. Quested, S. Evans, R. Paisey, N. Brown, A. Tucker, R. Paisey, F. Garrett, J. Hogg, P. Park, K. Williams, Philip Harvey, R. Wilcocks, S. Mason, J. Frost, C. Warren, P. Rocket, L. Bower, J. Roland, D. Brown, J. Youens, K. Stanton-King, H. Mungall, W. Maddison, D. Donnelly, S. King, P. Griffin, S. Smith, S. Church, G. Dunn, Apr Wilson, K. Palmer, P. Brown, D. Humphriss, A. Davidson, R. Rose, L. Armistead, S. Townsend, P. Poon, I. Peacock, N. Culverwell, M. Charlton, B. Connolly, J. Peacock, J. Barrett, J. Wain, W. Beeston, G. King, P. Hill, A. Boulton, A. Robertson, Katoulis, A. Olukoga, H. McDonald, S. Kumar, F. Abouaesha, B. Abuaisha, E. Knowles, S. Higgins, J. Booker, J. Sunter, K. Breislin, R. Parker, P. Raval, J. Curwell, H. Davenport, G. Shawcross, A. Prest, J. Grey, H. Cole, C. Sereviratne, R. Young, T. Dornan, J. Clyne, M. Gibson, I. O'Connell, L. Wong, S. Wilson, K. Wright, C. Wallace, D. McDowell, A. Burden, E. Sellén, R. Gregory, M. Roshan, N. Vaghela, M. Burden, C. Sherriff, J. Clarke, J. Grenfell, J. Tooke, K. Macleod, C. Searnark, M. Rammell, C. Pym, J. Stockman, C. Yeo, J. Piper, L. Leighton, E. Green, M. Hoyle, K. Jones, A. Hudson, A. James, A. Shore, A. Higham, B. Martin (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 317
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
P.M. Ridker, N.R. Cook, I.M. Lee (2005)
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in womenN Engl J Med, 352
B. Franklin, J. Kahn, N. Gordon, R. Bonow (2004)
A cardioprotective "polypill"? Independent and additive benefits of lifestyle modification.The American journal of cardiology, 94 2
J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E. Stein, W. Kruyer, A. Gotto (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA, 279 20
J. Stamler, R. Stamler, J. Neaton, D. Wentworth, M. Daviglus, D. Garside, A. Dyer, Kiang Liu, P. Greenland (1999)
Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women.JAMA, 282 21
(1983)
Incidence and mortality resultsEur Heart J, 4
Martha Daviglus, Kiang Liu, Philip Greenland, A. Dyer, D. Garside, L. Manheim, L. Lowe, Miriam Rodin, James Lubitz, Jeremiah Stamler (1998)
Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs.The New England journal of medicine, 339 16
T. Thom, Nancy Haase, W. Rosamond, V. Howard, J. Rumsfeld, T. Manolio, Zhi‐Jie Zheng, K. Flegal, Christopher O'Donnell, S. Kittner, D. Lloyd‐Jones, D. Goff, Yuling Hong, R. Adams, G. Friday, K. Furie, P. Gorelick, B. Kissela, J. Marler, J. Meigs, V. Roger, S. Sidney, P. Sorlie, J. Steinberger, S. Wasserthiel-Smoller, M. Wilson, P. Wolf (2006)
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation, 113 6
L. Melvin (2005)
Effects of estrogen with and without progestin on urinary incontinenceJournal of Family Planning and Reproductive Health Care, 31
Cott, L. J., Eischow, Itchell, N. A., Ides, Tephen, R. I., Ennard, Rlene, H. R., Ughes, Tevens, S. S., mith, Avid, D. M., Aughton, Imberli, Oan, Ichael, F. C., Iore, Imothy, B. B., Aker (1999)
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.The New England journal of medicine, 340 9
Ichiro Kawachi, G. Colditz, M. Stampfer, W. Willett, J. Manson, B. Rosner, F. Speizer, C. Hennekens (1993)
Smoking cessation and decreased risk of stroke in women.JAMA, 269 2
M. Wilmet (1983)
Multifactorial trial in the prevention of coronary heart disease: 3. Incidence and mortality results.European heart journal, 4 3
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais (2000)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, 342 3
I. Hjermann, I. Holme, K. Byre, P. Leren (1981)
EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE Report from the Oslo Study Group of a Randomised Trial in Healthy MenThe Lancet, 318
J. Dormandy, B. Charbonnel, D. Eckland, E. Erdmann, M. Massi-Benedetti, I. Moules, A. Skene, M. Tan, P. Lefèbvre, G. Murray, E. Standl, R. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R. Heine, L. Koranyi, M. Laakso, M. Mokáň, A. Norkus, V. Pīrāgs, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Škrha, U. Smith, J. Tatoň (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 366
F. Sacks, L. Svetkey, W. Vollmer, L. Appel, G. Bray, D. Harsha, E. Obarzanek, P. Conlin, E. Miller, D. Simons-Morton, N. Karanja, P. Lin, M. Aickin, Marlene Most-Windhauser, T. Moore, M. Proschan, J. Cutler (2001)
Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) dietThe New England Journal of Medicine, 344
L. Hansson, A. Zanchetti, S. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Ménard, K. Rahn, H. Wedel, S. Westerling (1998)
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 351
B. Mihaylova, A. Briggs, J. Armitage, S. Parish, A. Gray, R. Collins (2005)
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individualsThe Lancet, 365
G. Bakris (2001)
A practical approach to achieving recommended blood pressure goals in diabetic patients.Archives of internal medicine, 161 22
P. Greenland, M. Knoll, J. Stamler, J. Neaton, A. Dyer, D. Garside, P. Wilson (2003)
Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease EventsJAMA, 290
K. Pearce, C. Furberg, B. Psaty, J. Kirk (1998)
Cost-minimization and the number needed to treat in uncomplicated hypertension.American journal of hypertension, 11 5
L. Appel, T. Moore, T. Moore, E. Obarzanek, W. Vollmer, L. Svetkey, F. Sacks, G. Bray, T. Vogt, J. Cutler, M. Windhauser, P. Lin, N. Karanja, D. Simons-Morton, M. McCullough, J. Swain, P. Steele, M. Evans, E. Miller, D. Harsha (1997)
A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.The New England journal of medicine, 336 16
W. Verschuren, D. Jacobs, B. Bloemberg, D. Kromhout, A. Menotti, C. Aravanis, H. Blackburn, R. Buzina, A. Dontas, F. Fidanza (1995)
Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study.JAMA, 274 2
S. Franklin, M. Jacobs, N. Wong, G. L’italien, P. Lapuerta (2001)
Predominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives: Analysis Based on National Health and Nutrition Examination Survey (NHANES) IIIHypertension: Journal of the American Heart Association, 37
C. Wilhelmsson, D. Elmfeldt, Vedin Ja, G. Tibblin, L. Wilhelmsen (1975)
SMOKING AND MYOCARDIAL INFARCTIONThe Lancet, 305
P.S. Sever, B. Dahlof, N.R. Poulter (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet, 361
M. Daviglus, Kiang Liu, A. Pirzada, Lijing Yan, D. Garside, J. Feinglass, J. Guralnik, P. Greenland, J. Stamler (2003)
Favorable cardiovascular risk profile in middle age and health-related quality of life in older age.Archives of internal medicine, 163 20
R. Cooper, J. Cutler, P. Desvigne‐Nickens, S. Fortmann, Lawrence Friedman, R. Havlik, G. Hogelin, J. Marler, P. McGovern, G. Morosco, L. Mosca, T. Pearson, J. Stamler, D. Stryer, T. Thom (2000)
Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention.Circulation, 102 25
D. Williamson, E. Pamuk, M. Thun, D. Flanders, T. Byers, C. Heath (1995)
Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years.American journal of epidemiology, 141 12
M. Maciejewski, D. Patrick, D. Williamson (2005)
A structured review of randomized controlled trials of weight loss showed little improvement in health-related quality of life.Journal of clinical epidemiology, 58 6
Richard Hurt, David Sachs, Elbert Glover, Kenneth Offord, J. Johnston, Lowell Dale, M. Khayrallah, D. Schroeder, P. Glover, C. Sullivan, I. Croghan, P. Sullivan (1997)
A Comparison of Sustained-Release Bupropion and Placebo for Smoking CessationThe New England Journal of Medicine, 337
C. Baigent, C. Sudlow, R. Collins, R. Peto, Antithromboci Collaborat (2002)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ : British Medical Journal, 324
K. Miura, M. Daviglus, A. Dyer, Kiang Liu, D. Garside, J. Stamler, P. Greenland (2001)
Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry.Archives of internal medicine, 161 12
T. Rea, S. Heckbert, R. Kaplan, N. Smith, R. Lemaitre, B. Psaty (2002)
Smoking Status and Risk for Recurrent Coronary Events after Myocardial InfarctionAnnals of Internal Medicine, 137
(1985)
Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factorsPrev Med, 14
(1982)
Risk factor changes and mortality results: Multiple Risk Factor Intervention Trial Research GroupJAMA, 248
Jennifer Robinson, N. Maheshwari (2005)
A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.The American journal of cardiology, 95 3
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.JAMA, 289 19
L. Sjostrom, A.-K. Lindroos, M. Peltonen (2004)
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgeryN Engl J Med, 351
B. Davis (2000)
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.JAMA, 283 15
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
N. Benowitz, S. Gourlay (1997)
Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy.Journal of the American College of Cardiology, 29 7
J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaThe New England Journal of Medicine, 333
C. Bulpitt, N. Beckett, Jonathan Cooke, D. Dumitrascu, B. Gil‐Extremera, C. Nachev, Maria Nunes, R. Peters, J. Staessen, L. Thijs (2003)
Results of the pilot study for the Hypertension in the Very Elderly TrialJournal of Hypertension, 21
H. Colhoun, D. Betteridge, P. Durrington, G. Hitman, H. Neil, S. Livingstone, M. Thomason, M. Mackness, V. Charlton-menys, J. Fuller (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialThe Lancet, 364
J. Cutler, J. Neaton, S. Hulley, L. Kuller, O. Paul, J. Stamler (1985)
Coronary heart disease and all-causes mortality in the Multiple Risk Factor Intervention Trial: subgroup findings and comparisons with other trials.Preventive medicine, 14 3
A. Rosengren, A. Dotevall, H. Eriksson, L. Wilhelmsen (2001)
Optimal risk factors in the population: prognosis, prevalence, and secular trends; data from Göteborg population studies.European heart journal, 22 2
(1978)
Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling projectJ Chronic Dis, 31
S. Yusuf, P. Sleight, J. Pogue (2000)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med, 342
(1984)
The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart diseaseJAMA, 251
N. Wald, M. Law (2003)
A strategy to reduce cardiovascular disease by more than 80%BMJ : British Medical Journal, 326
I. Goldenberg, M. Jonas, A. Tenenbaum, V. Boyko, S. Matetzky, A. Shotan, S. Behar, H. Reicher-Reiss (2003)
Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease.Archives of internal medicine, 163 19
L. Gaal, A. Rissanen, A. Scheen, O. Ziegler, S. Rössner (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe studyThe Lancet, 365
B. Psaty, T. Lumley, C. Furberg, Gina Schellenbaum, M. Pahor, M. Alderman, N. Weiss (2003)
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.JAMA, 289 19
Lisheng Liu, J. Wang, L. Gong, Guozhang Liu, J. Staessen (1998)
Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertensionJournal of Hypertension, 16
A. Wolf, G. Colditz (1998)
Current estimates of the economic cost of obesity in the United States.Obesity research, 6 2
C. Siöström, Lauren Lissner, Lars Siostrom (1997)
Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects.Obesity research, 5 6
E. KoplanKate, P. DavidSean, A. RigottiNancy, 肖丹, 景行 (2000)
Smoking Cessation
K. Wilson, N. Gibson, A. Willan, D. Cook (2000)
Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies.Archives of internal medicine, 160 7
B. Dahlöf, P. Sever, N. Poulter, H. Wedel, D. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Östergren (2005)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled triThe Lancet, 366
T. Manolio, J. Chen, P. Sorlie (2004)
US Trends in prevalence of low coronary risk, National Health and Nutrition Examination Surveys (NHANES)Circulation, 109
F.M. Sacks, L.P. Svetkey, W.M. Vollmer (2001)
Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research GroupN Engl J Med, 344
M. Frick, Olli Elo, K. Haapa, O. Heinonen, P. Heinsalmi, Pekka Helo, J. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Mäenpää, M. Mälkönen, M. Mänttäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, E. Nikkilä (1987)
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.The New England journal of medicine, 317 20
L. Liu, J.G. Wang, L. Gong (1998)
Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension: Systolic Hypertension in China (Syst-China) Collaborative GroupJ Hypertens, 16
J. Staessen, J. Gąsowski, J. Wang, L. Thijs, E. Hond, J. Boissel, J. Coope, T. Ekbom, F. Gueyffier, Li-sheng Liu, K. Kerlikowske, S. Pocock, R. Fagard (2000)
Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trialsThe Lancet, 355
D. Annane, Eric Bellissant, P. Bollaert, Josef Briegel, D. Keh, Yizhak Kupfer (2004)
Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysisBMJ : British Medical Journal, 329
G. Colditz, Walter Willett, A. Rotnitzky, J. Manson (1995)
Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in WomenAnnals of Internal Medicine, 122
K.T. Knoops, L.C. Groot, D. Kromhout (2004)
Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE projectJAMA, 292
K. Fontaine, I. Barofsky, S. Bartlett, S. Franckowiak, R. Andersen (2004)
Weight loss and health-related quality of life: results at 1-year follow-up.Eating behaviors, 5 1
S.S. Franklin, M.J. Jacobs, N.D. Wong (2001)
Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensivesHypertension, 37
J.R. Downs, M. Clearfield, S. Weis (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPSJAMA, 279
(1989)
Final report on the aspirin component of the ongoing Physicians’ Health StudyN Engl J Med, 321
R. Kolotkin, Ross Crosby, G. Williams, G. Hartley, S. Nicol (2001)
The relationship between health-related quality of life and weight loss.Obesity research, 9 9
H. Perry, W. Smith, R. McDonald, D. Black, J. Cutler, C. Furberg, M. Greenlick, L. Kuller, H. Schnaper, J. Schoenberger, T. Vogt, P. Wolf, S. Hulley (1989)
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.Stroke, 20 1
D. Lloyd‐Jones, E. Leip, M. Larson, R. Vasan, D. Levy (2005)
Novel Approach to Examining First Cardiovascular Events After Hypertension OnsetHypertension, 45
J. Larosa, S. Grundy, D. Waters, C. Shear, P. Barter, J. Fruchart, A. Gotto, H. Greten, J. Kastelein, J. Shepherd, N. Wenger (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.The New England journal of medicine, 352 14
A. Amery, W. Birkenhäger, R. Brixko, C. Bulpitt, D. Clement, P. deLeeuw, D. Jf, M. Deruyttere, A. Deschaepdryver, C. Dollery, R. Fagard, H. Feltkamp, F. Forette, J. Forte, R. Hamdy, Henry Jf, A. Koistinen, G. Leonetti, P. Lund-johansen, J. Morris, A. Nissinen, E. O'Brien, K. O'malley, L. Terzoli, J. Tuomilehto, J. Webster, B. Williams (1986)
Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. EWPHE results: subgroup analysis based on entry stratificationJournal of Hypertension, 4
M. Brandle, M. Davidson, D. Schriger, B. Lorber, W. Herman (2003)
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.Diabetes care, 26 6
David Jacobs, Hisashi Adachi, I. Mulder, D. Kromhout, Alessandro Menotti, Aulikki Nissinen, H. Blackburn (1999)
Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study.Archives of internal medicine, 159 7
K. Ferraro, Ya-ping Su, R. Gretebeck, D. Black, S. Badylak (2002)
Body mass index and disability in adulthood: a 20-year panel study.American journal of public health, 92 5
J. Critchley, S. Capewell (2003)
Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review.JAMA, 290 1
D. Lloyd‐Jones, C. O’Donnell, R. D'Agostino, J. Massaro, H. Silbershatz, P. Wilson (2001)
Applicability of cholesterol-lowering primary prevention trials to a general population: the framingham heart study.Archives of internal medicine, 161 7
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen (2002)
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).JAMA, 288 23
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen, S. Oparil, J. Probstfield, P. Whelton, C. Nwachuku, D. Gordon, M. Proschan, Paula Einhom, C. Ford, L. Piller, I. Dunn, D. Goff, S. Pressel, Judy Bettencourt, Barbara DeLeon, Lara Simpson, J. Blanton, T. Geraci, Sandra Walsh, C. Nelson, Mahboob Rahman, Anne Juratovac, R. Pospíšil, L. Carroll, Sheila Sullivan, J. Russo, G. Barone, Rudy Christian, S. Feldman, T. Lucente, D. Calhoun, Kimo Jenkins, Peggy McDowell, Janice Johnson, C. Kingry, J. Alzate, K. Margolis, Leslie Holland-Klemme, B. Jaeger, J. Williamson, G. Louis, Pamela Ragusa, A. Williard, R. Ferguson, J. Tanner, J. Eckfeldt, R. Crow, J. Pelosi (2002)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA, 288 23
For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group
J.A. Staessen, R. Fagard, L. Thijs (1997)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial InvestigatorsLancet, 350
F.M. Sacks, M.A. Pfeffer, L.A. Moye (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levelsN Engl J Med, 335
M. Daviglus, J. Stamler, A. Pirzada, Lijing Yan, D. Garside, Kiang Liu, Renwei Wang, A. Dyer, D. Lloyd‐Jones, P. Greenland (2004)
Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality.JAMA, 292 13
C. Baigent, A. Keech, P. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 366
R. Turner, R. Holman (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.BMJ
(1991)
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP)JAMA, 265
J. Stamler, P. Elliott, B. Dennis, A. Dyer, H. Kesteloot, K. Liu, H. Ueshima, BF Zhou, for Group (2003)
INTERMAP: background, aims, design, methods, and descriptive statistics (nondietary)Journal of Human Hypertension, 17
I. Holme, I. Hjermann, A. Helgeland, P. Leren (1985)
The Oslo Study: diet and antismoking advice. Additional results from a 5-year primary preventive trial in middle-aged men.Preventive medicine, 14 3
(1995)
Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications TrialAm J Cardiol, 75
M. Daviglus, Kiang Liu, Lijing Yan, A. Pirzada, D. Garside, L. Schiffer, A. Dyer, P. Greenland, J. Stamler (2003)
Body mass index in middle age and health-related quality of life in older age: the Chicago heart association detection project in industry study.Archives of internal medicine, 163 20
J. Cromwell, W. Bartosch, M. Fiore, V. Hasselblad, T. Baker (1997)
Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.JAMA, 278 21
M. Fiore, W. Bailey, S. Cohen, S. Dorfman, M. Goldstein, E. Gritz, R. Heyman, J. Holbrook, C. Jaén, H. Lando, R. Mecklenburg, P. Mullen, L. Nett, L. Robinson, M. Stitzer, A. Tommasello, L. Villejo, M. Wewers, M. Bernard (1996)
Smoking cessation: Information for specialistsAmerican Family Physician, 53
AndrewJ. Coats (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 360
Roger Renfrew (1984)
Lipid Research Clinics Program.JAMA, 252 18
C. Pope, R. Burnett, G. Thurston, M. Thun, E. Calle, D. Krewski, J. Godleski (2003)
Cardiovascular Mortality and Long-Term Exposure to Particulate Air Pollution: Epidemiological Evidence of General Pathophysiological Pathways of DiseaseCirculation: Journal of the American Heart Association, 109
J. Stamler, M. Daviglus, D. Garside, A. Dyer, P. Greenland, J. Neaton (2000)
Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.JAMA, 284 3
A. Joseph, S. Norman, L. Ferry, A. Prochazka, E. Westman, B. Steele, Scott Sherman, Minot Cleveland, D. Antonuccio, Neil Hartman, P. McGovern (1996)
The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.The New England journal of medicine, 335 24
L. Sjöström, A. Lindroos, Markku Peltonen, J. Torgerson, C. Bouchard, B. Carlsson, S. Dahlgren, B. Larsson, K. Narbro, C. Sjöström, M. Sullivan, H. Wedel (2004)
Elective single-embryo transfer versus double-embryo transfer in in vitro fertilizationObstetrics & Gynecology, 105
C. Cohen, E. Kodas, G. Griebel (2005)
CB1 receptor antagonists for the treatment of nicotine addictionPharmacology Biochemistry and Behavior, 81
Lijing Yan, M. Daviglus, Kiang Liu, A. Pirzada, D. Garside, L. Schiffer, A. Dyer, P. Greenland (2004)
BMI and health-related quality of life in adults 65 years and older.Obesity research, 12 1
K. Uemura, Z. Píša (1988)
Trends in cardiovascular disease mortality in industrialized countries since 1950.World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales, 41 3-4
Diabetes Control, D. Nathan, S. Genuth, J. Lachin, P. Cleary, O. Crofford, M. Davis, L. Rand, C. Siebert (1993)
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.The New England journal of medicine, 329 14
G. Rose (1985)
European collaborative trial of multifactorial prevention of coronary heart disease.Lancet, 1 8534
Keith Clark (2000)
Body-Mass Index and Mortality in a Prospective Cohort of US Adults
S. Chaudhry, H. Krumholz, J. Foody (2004)
Systolic hypertension in older persons.JAMA, 292 9
B. Dahlöf, L. Hansson, L. Lindholm, B. Scherstén, T. Ekbom, P. Wester (1991)
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)The Lancet, 338
(1984)
The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol loweringJAMA, 251
(2000)
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 283
T. Strandberg, V. Salomaa, V. Naukkarinen, H. Vanhanen, S. Sarna, T. Miettinen (1991)
Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men.JAMA, 266 9
S. Yusuf (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. CommentaryThe Lancet, 360
J. Staessen, R. Fagard, L. Thijs, H. Celis, G. Arabidze, W. Birkenhäger, C. Bulpitt, P. Leeuw, C. Dollery, A. Fletcher, F. Forette, G. Leonetti, C. Nachev, E. Brien, J. Rosenfeld, J. Rodicio, J. Tuomilehto, A. Zanchetti (1997)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionThe Lancet, 350
K. Miura, P. Greenland, J. Stamler, Kiang Liu, M. Daviglus, H. Nakagawa (2004)
Relation of vegetable, fruit, and meat intake to 7-year blood pressure change in middle-aged men: the Chicago Western Electric Study.American journal of epidemiology, 159 6
Jeremiah Stamler, A. Dyer, R. Shekelle, James Neaton, R. Stamler (1993)
Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts.Cardiology, 82 2-3
Bonnie Hermanson, G. Omenn, R. Kronmal, B. Gersh (1988)
Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry.The New England journal of medicine, 319 21
J. Bosch, S. Yusuf, J. Pogue, P. Sleight, E. Lonn, B. Rangoonwala, R. Davies, J. Ostergren, J. Probstfield (2002)
Use of ramipril in preventing stroke: double blind randomised trialBMJ : British Medical Journal, 324
Cardiovascular disease (CVD), particularly coronary heart disease (CHD), remains a major cause of mortality, morbidity, and disability in the US and other Westernized societies. As a result of therapeutic and preventive measures to control the CVD/CHD epidemic, mortality has declined steadily during the last several decades with a consequent gain in life expectancy, but the 1990s witnessed a slowing of this decline. In response to these trends, a range of therapeutic regimens were developed to address adverse CVD risk factor levels and their deleterious effects. The scientific evidence regarding the efficacy, cost effectiveness, strengths, and limitations of a range of pharmacologic and lifestyle approaches to CVD prevention — both primary and secondary — are reviewed in depth. Clinical trials aimed at primary and secondary prevention of CVD have documented the efficacy and cost effectiveness of various drugs in lowering individual risk factor levels and in reducing clinical CVD events. More recently, the idea of a ‘polypill’ containing low doses of multiple drugs has generated much interest, with proponents arguing that, given the high prevalence of CVD risk factors and the effectiveness of pharmacologic interventions, such a drug combination would reduce CHD mortality by 88% if taken by all individuals aged α55 years. However, current treatments to control high BP and serum cholesterol, while effective, do not typically reduce morbidity and mortality to levels observed in low-risk individuals, i.e. those with favorable levels of all readily measured major risk factors. Rather, primary prevention of all major risk factors starting early in life is critical. Prospective population-based research has delineated multiple long-term benefits associated with low-risk status in young adulthood and middle age, i.e. markedly lower age-specific CVD and total mortality rates, increased life expectancy, lower healthcare costs, lower medication use and prevalence of chronic diseases, and higher self-reported quality of life at older ages. Unfortunately, despite declines in the prevalence of most major CVD risk factors, low-risk status remains rare among US adults. Data have also demonstrated that adverse levels of one or more major risk factors precede clinical CHD in 90% or more of all cases, undermining the assertion that major CVD risk factors account for ‘no more than 50%’ of CHD cases. Hence, while numerous treatment options exist for secondary prevention of CVD, strategies that focus on progressively increasing the proportion of low-risk individuals could greatly reduce the need for secondary prevention in the first place. Public health policies must focus on prevention of all major risk factors simultaneously, using lifestyle approaches from early ages onwards to reduce population CVD risk to endemic levels, rather than current epidemic levels.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.